kabutan

SanBio Company Limited(4592) Summary

4592
TSE Growth
SanBio Company Limited
1,777
JPY
+134
(+8.16%)
Dec 5, 11:30 am JST
11.45
USD
Dec 4, 9:30 pm EST
Result
PTS
outside of trading hours
1,777
Dec 5, 12:16 pm JST
Summary Chart Historical News Financial Result
PER
PBR
129
Yield
ー%
Margin Trading Ratio
159.54
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
1,643 JPY 10.59 USD
Previous Close Dec 4
1,643 JPY 10.57 USD
High Dec 5, 10:05 am
1,788 JPY 11.53 USD
Low Dec 5, 9:00 am
1,643 JPY 10.59 USD
Volume
1,966,000
Trading Value
3.42B JPY 0.02B USD
VWAP
1736.78 JPY 11.2 USD
Minimum Trading Value
177,700 JPY 1,145 USD
Market Cap
0.14T JPY 0.89B USD
Number of Trades
6,393
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
High
1-Year Average
7,759
1-Year High Oct 17, 2025
46,775
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 11,800 7,036,700 596.33
Nov 21, 2025 14,400 7,069,400 490.93
Nov 14, 2025 9,800 7,231,500 737.91
Nov 7, 2025 9,900 7,277,300 735.08
Oct 31, 2025 10,200 6,844,000 670.98
Company Profile
SanBio Company Limited is a biotech venture specializing in the development of regenerative cell therapies. Their products show promise for treating neurological disorders.
Sector
Pharmaceuticals
SanBio Company Limited is a biotech venture primarily focused on the research and development of regenerative cell medicines. Founded in the United States, the company later expanded into Japan. Their flagship product, SB623, is an allogeneic neural regenerative cell therapy targeting central nervous system disorders. The company has submitted a regulatory application in Japan for chronic traumatic brain injury and aims to expand its indications to include stroke and intracerebral hemorrhage. SanBio possesses proprietary cell culture and manufacturing technologies and has secured product supply rights. Given SB623's strong neuroprotective properties, the company is also exploring its potential in other conditions such as retinal diseases. SanBio employs a business model that combines in-house development with licensing agreements with partner companies. The company places a strong emphasis on securing intellectual property rights and is pursuing a business strategy with global expansion in mind.